MDT-AP-0549
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 3
- os_event
- true
- age_years
- 3
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.240527695
- umap2_2d
- 0.625400426
- umap1_3d
- -0.518153791
- umap2_3d
- -2.103468617
- umap3_3d
- -0.816343439
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.720
- MYC_TARGETS_V1+0.550
- E2F_TARGETS+0.510
- G2M_CHECKPOINT+0.430
- UNFOLDED_PROTEIN_RESPONSE+0.390
- DNA_REPAIR+0.380
- TNFA_SIGNALING_VIA_NFKB+0.360
- MTORC1_SIGNALING+0.310
- OXIDATIVE_PHOSPHORYLATION+0.310
- ALLOGRAFT_REJECTION+0.300
Top 10 suppressed
- PROTEIN_SECRETION-0.310
- UV_RESPONSE_DN-0.250
- HEDGEHOG_SIGNALING-0.230
- APICAL_SURFACE-0.180
- APICAL_JUNCTION-0.120
- HEME_METABOLISM-0.120
- MITOTIC_SPINDLE-0.120
- PI3K_AKT_MTOR_SIGNALING-0.110
- XENOBIOTIC_METABOLISM-0.090
- MYOGENESIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2118 | Med | Medulloblastoma | 0.917 |
| 2 | BS_R439VVPK | Med | Medulloblastoma | 0.880 |
| 3 | MDT-AP-0532 | Med | Medulloblastoma | 0.862 |
| 4 | 060C8F0B-DAB8-43DB-80C9-3404AFCC0B7D | — | — | 0.850 |
| 5 | BS_HE57E1RP | Med | Medulloblastoma | 0.850 |
| 6 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.847 |
| 7 | MDT-AP-0509 | Med | Medulloblastoma | 0.836 |
| 8 | MDT-AP-0203 | Med | Medulloblastoma | 0.834 |
| 9 | MDT-AP-0370 | Med | Medulloblastoma | 0.832 |
| 10 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.720 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |